Mr. Peter Bakema reports

CRITICAL MILESTONE: CVR MEDICAL TO LAUNCH PIVOTAL TRIALS

CVR Medical Corp. will start clinical trials on Monday, March 5, 2018, for the carotid stenotic scan (CSS) device. This anticipated milestone represents the final phase of clinical substantiation which CVR will use to support the upcoming FDA submission. Initially, Thomas Jefferson University Hospital (Philadelphia, Pa.) and Henry Ford Hospital (Detroit, Mich.) will act as the key pivotal trials locations, but CVR plans to expand the footprint as other locations come on-line, increasing the speed of data procurement and shortening the time frame to submission.

"The project is gaining momentum," comments CVR chief operating officer/executive vice-president, Tony Robinson, "and this step is definitely one of the more critical milestones we have been working toward. Whether the clinical trials, the manufacturing agreement with Canon, or the nearing FDA submission with the support of Duval & Associates; they all bring us one step closer to realizing our goal of improving health care."

The clinical substantiation will be supported with five devices across the Thomas Jefferson footprint, three devices within the Henry Ford Healthcare System and multiple devices within trials at pending clinical sites. The spectrum of locations will support a diverse and rapid acquisition process.

About CVR Medical Corp.

CVR Medical is a company that is involved in an equal-part joint venture with CVR Global Inc. The joint venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic and low-frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis.

We seek Safe Harbor.